SCHEMBL764196

SCHEMBL764196

COc1ccc2[nH]c3c(c2c1)CCNC3c1cccnc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 4/20 0.61
HTR2B P41595 6/20 0.61
ALDH1A1 P00352 1/20 0.61
MAPT P10636 1/20 0.61
HTR2C P28335 13/20 0.58
HTR2A P28223 12/20 0.58
MAPKAPK2 P49137 3/20 0.55
MAPKAPK5 Q8IW41 1/20 0.55
CHRM4 P08173 1/20 0.54
DRD2 P14416 1/20 0.54
HTR1A P08908 2/20 0.53
DRD4 P21917 2/20 0.53
HTR1D P28221 2/20 0.53
HTR1B P28222 2/20 0.53
HTR1E P28566 2/20 0.53
HTR5A P47898 2/20 0.53
HTR6 P50406 2/20 0.53
DRD3 P35462 1/20 0.53
HTR3A P46098 1/20 0.53
SIGMAR1 Q99720 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL765058 0.86 HTR7 (0.72) HTR7HTR2BALDH1A1MAPTHTR2C
SCHEMBL8403033 0.84 MAPKAPK2 (0.62) HTR7HTR2CHTR2AMAPKAPK2
SCHEMBL764888 0.84 HTR2B (0.72) HTR7HTR2BALDH1A1MAPTHTR2C
SCHEMBL763644 0.83 HTR2C (0.75) HTR2BHTR2CHTR2A
SCHEMBL26022215 0.83 HTR2C (0.77) HTR2BHTR2CHTR2A
SCHEMBL3567786 0.81 HTR2A (0.75) HTR7HTR2BALDH1A1MAPTHTR2C
SCHEMBL30274487 0.81 HTR7 (0.72) HTR7ALDH1A1HTR2CHTR2AMAPKAPK2
SCHEMBL1520425 0.79 HTR2C (0.78) HTR7HTR2BALDH1A1MAPTHTR2C
SCHEMBL30274482 0.78 HTR2B (0.63) HTR7HTR2BALDH1A1MAPTHTR2C
SCHEMBL763727 0.77 HTR7 (0.72) HTR7HTR2BALDH1A1MAPTHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130171103-A1 METHODS FOR TREATING VIRAL CONDITIONS PTC THERAPEUTICS, INC. (US) 2013-07-04 US disclosed
US-20130171103-A1 METHODS FOR TREATING VIRAL CONDITIONS PTC THERAPEUTICS, INC. (US) 2013-07-04 US disclosed
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 US disclosed
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 US disclosed
US-8367694-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-05 US disclosed
US-8367694-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-05 US disclosed
US-20120129841-A1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2012-05-24 US disclosed
US-20120129841-A1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2012-05-24 US disclosed
EP-2431369-A2 Carboline derivatives useful in the inhibition of angiogenesis PTC Therapeutics, Inc. (US) 2012-03-21 EP disclosed
EP-1871375-B1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER PTC THERAPEUTICS INC (US) 2012-02-29 EP disclosed
US-20090209521-A9 Inhibition of VEGF Translation PTC THERAPEUTICS, INC. 2009-08-20 US disclosed
US-20090209521-A9 Inhibition of VEGF Translation PTC THERAPEUTICS, INC. 2009-08-20 US disclosed
WO-2008127714-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed
WO-2008127715-A1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed
US-20080064683-A1 Inhibition of VEGF Translation PTC THERAPEUTICS, INC. 2008-03-13 US disclosed
US-20080064683-A1 Inhibition of VEGF Translation PTC THERAPEUTICS, INC. 2008-03-13 US disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 US disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 US disclosed
US-20070254878-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2007-11-01 US disclosed
US-20070254878-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064683-A1 Inhibition of VEGF Translation EIF4E, EIF4EBP1, VEGFA HTR7 3313/4885HTR2B 3976/4885ALDH1A1 3364/4885
US-20070254878-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES VEGFA, FLT4, FLT1 HTR7 1737/4885HTR2B 2623/4885ALDH1A1 1340/4885
US-20120129841-A1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES VEGFA, FLT4, FLT1 HTR7 1701/4885HTR2B 2539/4885ALDH1A1 1479/4885
US-20090209521-A9 Inhibition of VEGF Translation EIF4E, EIF4EBP1, VEGFA HTR7 3313/4885HTR2B 3976/4885ALDH1A1 3364/4885
US-20130171103-A1 METHODS FOR TREATING VIRAL CONDITIONS EIF2AK2, POLRMT, POLM HTR7 4338/4885HTR2B 4572/4885ALDH1A1 3386/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF HTR7 1021/4885HTR2B 839/4885ALDH1A1 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.